These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27272731)

  • 1. Chronic kidney disease-mineral and bone disorder: Guidelines for diagnosis, treatment, and management.
    Moschella C
    JAAPA; 2016 Jul; 29(7):21-9. PubMed ID: 27272731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today?
    Melamed ML; Buttar RS; Coco M
    Adv Chronic Kidney Dis; 2016 Jul; 23(4):262-9. PubMed ID: 27324680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Secondary osteoporosis. Disordered bone metabolism in chronic kidney disease.].
    Nakagawa Y; Komaba H
    Clin Calcium; 2018; 28(12):1611-1618. PubMed ID: 30487325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder.
    Hanudel MR; Salusky IB
    Curr Osteoporos Rep; 2017 Jun; 15(3):198-206. PubMed ID: 28455644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults.
    Bellorin-Font E; Ambrosoni P; Carlini RG; Carvalho AB; Correa-Rotter R; Cueto-Manzano A; Jara A; Jorgetti V; Negri AL; Olaizola I; Salusky I; Slatopolsky E; Weisinger JR; ;
    Nefrologia; 2013; 33 Suppl 1():1-28. PubMed ID: 23629678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [K/DOQI clinical practice guidelines for management of renal osteodystrophy in predialysis patients].
    Okada N; Tsubakihara Y
    Clin Calcium; 2004 May; 14(5):698-706. PubMed ID: 15577030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone and mineral guidelines for patients with chronic kidney disease: a call for revision.
    Andress DL
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):179-83. PubMed ID: 18057310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.
    Ota M; Takahata M; Shimizu T; Kanehira Y; Kimura-Suda H; Kameda Y; Hamano H; Hiratsuka S; Sato D; Iwasaki N
    Osteoporos Int; 2017 Apr; 28(4):1481-1490. PubMed ID: 27933339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adynamic bone disease: from bone to vessels in chronic kidney disease.
    Bover J; Ureña P; Brandenburg V; Goldsmith D; Ruiz C; DaSilva I; Bosch RJ
    Semin Nephrol; 2014 Nov; 34(6):626-40. PubMed ID: 25498381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current concepts and management strategies in chronic kidney disease-mineral and bone disorder.
    Chauhan V; Kelepouris E; Chauhan N; Vaid M
    South Med J; 2012 Sep; 105(9):479-85. PubMed ID: 22948328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update.
    Ketteler M; Block GA; Evenepoel P; Fukagawa M; Herzog CA; McCann L; Moe SM; Shroff R; Tonelli MA; Toussaint ND; Vervloet MG; Leonard MB
    Ann Intern Med; 2018 Mar; 168(6):422-430. PubMed ID: 29459980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hyperphosphatemia in Chronic Kidney Disease (CKD)].
    Wang J; Zhang XY; Guan YF
    Sheng Li Ke Xue Jin Zhan; 2015 Aug; 46(4):241-4. PubMed ID: 26669072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease.
    Lundquist AL; Nigwekar SU
    Curr Opin Nephrol Hypertens; 2016 Mar; 25(2):120-6. PubMed ID: 26785065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Guideline for the management of chronic kidney disease-related mineral and bone disorders (CKD-MBD)].
    Kakuta T
    Clin Calcium; 2007 May; 17(5):752-9. PubMed ID: 17471006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic Kidney Disease - Update 2018].
    Ketteler M; Wanner C
    Dtsch Med Wochenschr; 2018 Feb; 143(3):169-173. PubMed ID: 29409087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: Addressing risk factors in chronic kidney disease mineral and bone disorder: can we influence patient-level outcomes?
    O'Shea S; Johnson DW
    Nephrology (Carlton); 2009 Jun; 14(4):416-27. PubMed ID: 19563384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing bone mineral disorders in CKD: an overview of current therapies.
    Delaney M
    J Ren Care; 2009 Mar; 35 Suppl 1():107-10. PubMed ID: 19222741
    [No Abstract]   [Full Text] [Related]  

  • 19. Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease.
    Zhou C; Wang F; Wang JW; Zhang LX; Zhao MH
    Chin Med J (Engl); 2016 Oct; 129(19):2275-80. PubMed ID: 27647184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.
    Sugatani T; Agapova OA; Fang Y; Berman AG; Wallace JM; Malluche HH; Faugere MC; Smith W; Sung V; Hruska KA
    Kidney Int; 2017 Jan; 91(1):86-95. PubMed ID: 27666759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.